Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 2427 of 6351
-
New hope for tough prostate cancer? early trial begins
Disease control Recruiting nowThis study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).
Phase 1 • Sponsor: Janux Therapeutics • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Lifestyle coaching may be key to keeping weight off after stopping obesity drugs
Disease control CompletedPharmacotherapy becomes an important and effective approach to improve body weight. However, it still remains unclear how to manage potential fluctuation after its cessation. Lifestyle change is the foundation and included as a part of clinical routine in real-world, therefore, w…
Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Laparoscopic showdown: which surgical technique helps gastric cancer patients recover better?
Symptom relief CompletedThe aim of this study is comparing the short-term quality of life between laparoscopy-assisted distal gastrectomy and totally laparoscopic distal gastrectomy for gastric cancer.
Sponsor: Fudan University • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
New Large-Vessel heart stent tested in Real-World patients
Disease control OngoingSPIRIT XLV PAS is a prospective, single arm, multi-center, US and OUS post-approval observational study to evaluate the continued safety and effectiveness of the XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS) Large Vessel (LV) sizes (diameter 4.5 mm…
Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Common antifungal drug may help prevent esophageal cancer recurrence
Disease control OngoingRecurrent Barrett's esophagus (BE) that occurs at the rate of 12.4%/year is the Achilles heel of the endoscopic treatment of high-risk BE. Over time, after eradication, BE ultimately recurs in as many as 30-50% of the patients putting them at risk for esophageal adenocarcinoma (E…
Early phase 1 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Guam school curriculum aims to curb teen vaping and betel nut use
Prevention CompletedThe people of the U.S. Affiliated Pacific Islands (USAPI) face higher cancer incidence, especially lung/bronchia and head-and-neck cancer, and poorer cancer outcomes, compared with the U.S. nationally. This may partly be driven by the high rates of cigarette smoking and betel (ar…
Sponsor: University of Guam • Aim: Prevention
Last updated Jun 27, 2026 12:30 UTC
-
Video games could be the new treatment for lazy eye
Symptom relief Recruiting nowAmblyopia, a developmental abnormality that impairs spatial vision, is a major cause of vision loss, resulting in reduced visual acuity and reduced sensitivity to contrast. This study uses psychophysical measures to study neural plasticity in both adults and children with amblyop…
Sponsor: Nova Southeastern University • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
New scan could spot lung cancer in the brain more clearly
Diagnosis Recruiting nowThis study investigates fluorine-18-AlphaVBeta6-BP (\[18F\]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that \[18F\]-αvβ6-BP PET/Computed Tomography (CT) is a sensitive tool fo…
Phase 1 • Sponsor: University of California, Davis • Aim: Diagnosis
Last updated Jun 27, 2026 09:08 UTC
-
Hospital alcohol therapy boosts recovery engagement
Disease control CompletedThis study is a 3-arm randomized clinical trial to evaluate the effectiveness of hospital-initiated Alcohol Use Disorder treatment, involving a Brief Negotiated Interview (with referral and telephone booster) alone, BNI+facilitated provision of MAUD, BNI+facilitated provision of …
Sponsor: Yale University • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Timing matters: study tests best moment to remove dead tissue in pancreatitis
Disease control CompletedAcute pancreatitis is one of the most common diagnoses made in gastroenterology wards worldwide which causes a great deal of pain and expense along with fatal complications. Approximately, 10-20% of patients progress to necrotizing pancreatitis that result in significant morbidit…
Sponsor: University of Tehran • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New cholesterol drug inclisiran tested in everyday patients
Disease control OngoingThis observational prospective study aims to evaluate the LDL-C change and adherence to inclisiran in combination with other lipid lowering therapies or lipid lowering treatments (LLTs) under conditions of routine clinical practice.
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Could less radiation be enough for head and neck cancer?
Disease control Recruiting nowThe purpose of this study is to test the treatment approach of de-escalated radiation and chemotherapy followed by a planned neck dissection surgery in people with head and neck cancer. The study will look at how effective the treatment approach is against participants' cancer.
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New depression pill shows promise in early trial
Symptom relief CompletedThis is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (QD) extended-release (XR) capsules for the treatment of adult subjects diagnosed with Major Depressive Di…
Phase 2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Could a buddy system for HIV care improve lives?
Disease control Recruiting nowThe overall goal of this study is to test whether dyadic and focused case management will (1) improve financial wellbeing, (2) improve access to food, (3) increase linkage and retention rates for individuals living with HIV or those taking PrEP (PrEP persistence), and (4) increas…
Sponsor: University of Chicago • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New HIV vaccine candidate enters early safety testing
Vaccine CompletedThis study will evaluate the safety and tolerability (including reactogenicity) of candidate vaccine A244/B.63521 with Army Liposome Formulation (ALF) mixed with the saponin QS-21(Quillaja saponaria-21) (ALFQ) adjuvant. The purpose of this phase I randomized, double-blind clinica…
Phase 1 • Sponsor: U.S. Army Medical Research and Development Command • Aim: Vaccine
Last updated Jun 27, 2026 09:03 UTC
-
New drug for rare blood cancer studied in everyday practice
Disease control Recruiting nowPolycythaemia vera (PV) is associated with a reduced quality of life, a high rate of vascular events, and an intrinsic risk of disease evolution. The results of several randomised trials for the treatment with new cytoreductive agents are now available, among which a new ropegyla…
Sponsor: FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug combo aims to shrink pancreatic tumors before surgery
Disease control OngoingThis study is a single-arm, phase I trial, up to 16 participants with resectable PDA. The study will examine the efficacy of the mutant IDH1 inhibitor ivosidenib, in conjunction with standard-of-care mFOLFIRINOX in the neoadjuvant setting.
Phase 1 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 13:51 UTC
-
New hope for hard-to-treat breast cancer? early trial combines two targeted drugs
Disease control CompletedA phase 1b study to assess the combination of ARV-471 and everolimus in participants with advanced or metastatic ER+/HER2- breast cancer.
Phase 1 • Sponsor: Arvinas Estrogen Receptor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Heart pump patients get new hope from diabetes drug
Disease control CompletedThe main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure (HF) patients with left ventricular assist devices (LVAD).
Phase 4 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Implantable heart attack alert device tested in Real-World patients
Disease control Recruiting now500 Patients (minimum) will be enrolled following commercial implant. Will be treated by their physicians using the standard of care. Standard of care for the Guardian includes an in-office initial programming visit 7-14 days following implant and every 6 months.
Sponsor: Angel Medical Systems • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC